Further studies also are needed to determine if supplementation of phosphatidylcholine also attenuates the progression of MASLD in human beings, and if this also is related to changes in LRH-1/PPARγ2/NFκB signaling. This evidence concerns the gene PPARG and metabolic dysfunction-associated steatotic liver disease.